Biotech News
Related news
ERASErasca2026-07-13 20:01 EST
Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
ERASErasca2026-08-24 12:00 EST
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
FATEFate Therapeutics2026-08-14 11:00 EST
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
IDYAIDEAYA Biosciences2026-06-15 10:00 EST
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
RVMDRevolution Medicines2026-07-02 12:00 EST
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
RVMDRevolution Medicines2026-06-23 12:00 EST
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
LEGNLegend Biotech Corporation2026-06-15 12:00 EST
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
IDYAIDEAYA Biosciences2026-07-27 10:00 EST
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
MGNXMacroGenics2026-07-23 20:01 EST
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
KURAKura Oncology2026-06-11 12:02 EST
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
Erasca
RAS/MAPK Precision Oncology Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct RAS inhibition. ERAS-0015 ERAS-0015 is a pan-RAS molecular glue being evaluated in the AURORAS clinical program....
Recent company news
ERASErasca2026-08-24 12:00 EST
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
ERASErasca2026-08-11 20:01 EST
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
ERASErasca2026-08-10 20:01 EST
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ERASErasca2026-08-10 12:00 EST
Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D
ERASErasca2026-07-15 20:01 EST
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Stock data
- Close
- 17.63 USD
- Market cap
- 4.19B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States